Drug Details

General Information of the Drug (ID: DR2830)
Name
Rev-caspase-3
Disease Ovarian cancer [ICD-11: 2C73] Investigative [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Flavopiridol      Dysoxylum binectariferum     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model OVCAR-3 CVCL_0465 Ovarian serous adenocarcinoma Homo sapiens
                    In-vivo Model 1*107 OVCAR3 cells in 0.2 ml PBS were inoculated subcutaneously into the dorsal flank of female mice (4 to 6 weeks old and weighing 16 to 20 g).
                    Experimental
                    Result(s)		 The sequential combination of rev-caspase-3 and flavopiridol result in significant synergistic cell killing effects, significant tumor growth suppression and extended survival of mice bearing OVCAR3 cells.
Target and Pathway
Target(s) Glutamate-cysteine ligase catalytic (GCLC)  Molecule Info  [3]
References
Reference 1 Autocatalytic caspase-3 driven by human telomerase reverse transcriptase promoter suppresses human ovarian carcinoma growth in vitro and in mice. Int J Gynecol Cancer. 2013 May;23(4):642-9.
Reference 2 Sequential combination therapy with flavopiridol and autocatalytic caspase-3 driven by amplified hTERT promoter synergistically suppresses human ovarian carcinoma growth in vitro and in mice. J Ovarian Res. 2014 Dec 21;7:121.
Reference 3 L-S,R-buthionine sulfoximine: historical development and clinical issues. Chem Biol Interact. 1998 Apr 24;111-112:239-54.
 Download Picture         KEGG Link